The Cooper Companies, Inc. Provides Consolidated Earnings Guidance for the Third Quarter, Fourth Quarter and Full Year of Fiscal 2022
June 02, 2022 at 04:15 pm EDT
Share
The Cooper Companies, Inc. provided consolidated earnings guidance for the third quarter, fourth quarter and full year of fiscal 2022. For the full year, the company expects total revenue to be in the range of $3,280 million to $3,312 million (organic growth of 9% to 10%).
The company expects third quarter earnings to be similar to second quarter driven by the significant negative impact of currency for the quarter.
For the fourth quarter, the company expects a rebound in EPS, led by a lower pound flowing through its cost of goods, helping CooperVision's gross margin.
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision and CooperSurgical. CooperVision is engaged in the contact lens industry. CooperVisionâs products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys, Biofinity toric & Biofinity XR toric, Biofinity multifocal, Biofinity toric multifocal, clariti 1 day, clariti 1 day toric, clariti 1 day multifocal, MiSight 1 day, Avaira Vitality and Avaira Vitality toric. CooperSurgical is a fertility and womenâs health company dedicated to assisting women, babies and families around the world. CooperSurgical provides a range of products and services with an emphasis on improving fertility solutions, empowering office-based care, and advancing hospital care within womenâs health. CooperSurgicalâs brands include Paragard, ER-Complete, Fetal Pillow, INSORB, PGT-Complete, RUMI II and others.
THE COOPER COMPANIES, INC. 
